Phase 3 Clinical Trials With Primary Completion Dates in November 2019
This is a list of Phase 3 trials with primary completion dates in November 2019 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
|Symbol||Company||Primary Completion Date||Phase||NCT ID||Title|
|ARDX||Ardelyx, Inc.||2019-11-01||Phase 3||NCT03427125||A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis|
|BCRX||BioCryst Pharmaceuticals, Inc.||2019-11-01||Phase 3||NCT03873116||Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan|
|BFRA||Biofrontera AG||2019-11-01||Phase 3||NCT03573401||Study to Evaluate the Safety and Efficacy of BF-200 ALA (AmeluzÂ®) and BF-RhodoLEDÂ® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).|
|CARA||Cara Therapeutics, Inc.||2019-11-01||Phase 3||NCT03281538||Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus|
|ICLR||ICON plc||2019-11-01||Phase 3||NCT02794168||Efficacy of VAS203 (Ronopterin) in Patients With Moderate and Severe Traumatic Brain Injury|
|SLGL||Sol-Gel Technologies Ltd.||2019-11-01||Phase 3||NCT03761810||A Study of S6G5T 3 in the Treatment of Acne Vulgaris|
|SNY||Sanofi||2019-11-01||Phase 3||NCT01471444||Fludarabine-IV Busulfan Â± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)|
|TGTX||TG Therapeutics, Inc.||2019-11-01||Phase 3||NCT02612311||Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Untreated and Previously Treated Chronic Lymphocytic Leukemia|